News & Media
Feb 3, 2021
VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome
VectivBio Holding AG, a clinical-stage biotechnology company developing innovative treatments for severe rare conditions with high unmet medical need, today announced that the first patient has been dosed in its pivotal phase 3 trial of apraglutide in short bowel syndrome (SBS).
Nov 4, 2020
VectivBio Strengthens Business Development Capabilities with Key Appointments
VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced the appointments of Sarah Holland, Ph.D., as Chief Business Officer and Aditya Venugopal, Ph.D., as Vice President of Business Development. Dr. Holland will be based in Switzerland and Dr. Venugopal will be based in the U.S., further expanding the company’s global reach.
Oct 15, 2020
VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases
VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced it has closed a $110 million crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfer Initiative and Cowen Healthcare Investments.
Sep 15, 2020
VectivBio Appoints Nader N. Youssef, M.D., as Senior Vice President, Head of Global Clinical Development and Medical Affairs
VectivBio AG, a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases, today announced it has appointed Nader N. Youssef, M.D., as Senior Vice President, Head of Global Clinical Development and Medical Affairs
Feb 6, 2020
VectivBio Adds Commercial Expertise with the Appointment of Kevin Harris as Chief Commercial Officer
VectivBio AG, a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases, today announced it has appointed Kevin Harris as chief commercial officer.
Feb 3, 2021
VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome
VectivBio Holding AG, a clinical-stage biotechnology company developing innovative treatments for severe rare conditions with high unmet medical need, today announced that the first patient has been dosed in its pivotal phase 3 trial of apraglutide in short bowel syndrome (SBS).
Nov 4, 2020
VectivBio Strengthens Business Development Capabilities with Key Appointments
VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced the appointments of Sarah Holland, Ph.D., as Chief Business Officer and Aditya Venugopal, Ph.D., as Vice President of Business Development. Dr. Holland will be based in Switzerland and Dr. Venugopal will be based in the U.S., further expanding the company’s global reach.
Oct 15, 2020
VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases
VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced it has closed a $110 million crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfer Initiative and Cowen Healthcare Investments.
Sep 15, 2020
VectivBio Appoints Nader N. Youssef, M.D., as Senior Vice President, Head of Global Clinical Development and Medical Affairs
VectivBio AG, a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases, today announced it has appointed Nader N. Youssef, M.D., as Senior Vice President, Head of Global Clinical Development and Medical Affairs
Feb 6, 2020
VectivBio Adds Commercial Expertise with the Appointment of Kevin Harris as Chief Commercial Officer
VectivBio AG, a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases, today announced it has appointed Kevin Harris as chief commercial officer.